The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Clinical & Manufacturing

New study reveals DSM’s Fruitflow® activates gut-heart axis that can modulate gut microbiota leading to cardiovascular benefits
Basic & Discovery Research

New study reveals DSM’s Fruitflow® activates gut-heart axis that can modulate gut microbiota leading to cardiovascular benefits

JAN 24, 2023
NIH-supported clinical trial of phage therapy for cystic fibrosis begins
Clinical & Manufacturing

NIH-supported clinical trial of phage therapy for cystic fibrosis begins

OCT 19, 2022
MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies
Clinical & Manufacturing

MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies

FEB 9, 2022
BioGaia’s probiotic reduces inflammation in patients with diverticulitis
Clinical & Manufacturing

BioGaia’s probiotic reduces inflammation in patients with diverticulitis

FEB 9, 2022
Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection
Clinical & Manufacturing

Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection

JAN 24, 2022
Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD
Clinical & Manufacturing

Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD

DEC 6, 2021
Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
Clinical & Manufacturing

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

NOV 19, 2021
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
Basic & Discovery Research

Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection

NOV 12, 2021
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Clinical & Manufacturing

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

OCT 5, 2021
Clinical Trial Expert Discussion: Study Design for Microbiome Therapies
Clinical & Manufacturing

Clinical Trial Expert Discussion: Study Design for Microbiome Therapies

SEP 28, 2021
Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis
Clinical & Manufacturing

Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis

SEP 27, 2021